Adele Fielding | Academic Influence

Adele Fielding's AcademicInfluence.com Rankings

Adele Fielding

Computer Science

#11136

World Rank

#11765

Historical Rank

Machine Learning

#5090

World Rank

#5153

Historical Rank

Artificial Intelligence

#5487

World Rank

#5563

Historical Rank

Database

#8163

World Rank

#8512

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Adele Fielding's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Adele Fielding Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Adele Kay Fielding is a British physician-scientist who is a Professor of Haematology at University College London. Fielding was President of the British Society for Haematology from 2020 until 2022.

(See a Problem?)

Adele Fielding's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia (2017) (1188)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. (2015) (951)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. (2007) (734)
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin (2006) (706)
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. (2005) (684)
Hepatitis B transmission from contaminated cryopreservation tank (1995) (419)
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers (2007) (405)
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). (2009) (327)
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 (2010) (322)
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. (2014) (301)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. (2017) (292)
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. (2009) (265)
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. (2001) (254)
Acquired skewing of X‐chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age (1997) (245)
Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. (1996) (218)
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2016) (209)
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia (2016) (181)
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial (2012) (160)
Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. (1997) (150)
Listeria ivanovii infection in a patient with AIDS. (1994) (146)
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (2016) (142)
Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 (2010) (133)
Strength of Envelope Protein Interaction Modulates Cytopathicity of Measles Virus (2002) (124)
Activated Stromal Cells Transfer Mitochondria to Rescue Acute Lymphoblastic Leukaemia Cells from Oxidative Stress. (2019) (114)
Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. (2003) (114)
Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. (2015) (112)
IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. (2012) (107)
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. (2011) (105)
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. (2010) (100)
The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia (2013) (97)
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. (2010) (93)
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia (2016) (93)
Measles to the Rescue: A Review of Oncolytic Measles Virus (2016) (92)
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial (2016) (90)
Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for (2018) (90)
Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. (1994) (89)
An oncolytic measles virus engineered to enter cells through the CD20 antigen. (2003) (88)
Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma (2004) (87)
High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis (2008) (86)
G‐CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial (1997) (78)
IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. (2014) (75)
Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. (1998) (73)
A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy (2000) (70)
Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. (2014) (69)
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia (2018) (65)
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. (2018) (62)
Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD (2012) (61)
A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. (2000) (59)
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. (2010) (58)
Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. (2010) (58)
Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (2010) (57)
Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation (2010) (56)
Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA) (2015) (50)
APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL (2017) (47)
Measles as a potential oncolytic virus (2005) (46)
Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. (2016) (45)
Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia (2008) (44)
UKALLXII / ECOG 2993 : addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia (2014) (43)
Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency. (2011) (42)
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial (2013) (42)
Characterisation of the genomic landscape of CRLF2‐rearranged acute lymphoblastic leukemia (2017) (42)
Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome)--a report on 40 cases from a single centre. (1992) (41)
Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia‐negative peripheral blood stem cells (1997) (39)
The treatment of adults with acute lymphoblastic leukemia. (2008) (38)
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: a broader range of options, improved outcomes, and more therapeutic dilemmas. (2015) (35)
Accessory cells do not contribute to G‐CSF or IL‐6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation (1995) (35)
Risk‐stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia (2013) (34)
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission (2009) (34)
High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome (2014) (33)
Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial (2010) (31)
Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). (2014) (29)
Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD (2014) (29)
Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. (2011) (28)
Molecular Classification Improves Risk Assessment in Adult BCR-ABL1-negative B-ALL. (2021) (28)
Does Imatinib Change the Outcome in Philapdelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study. (2007) (26)
Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. (2016) (26)
Current therapeutic strategies in adult acute lymphoblastic leukemia. (2011) (24)
Attenuated, Oncolytic, but Not Wild-Type Measles Virus Infection Has Pleiotropic Effects on Human Neutrophil Function (2012) (24)
Prophylaxis against late infection following splenectomy and bone marrow transplant. (1994) (23)
Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. (2011) (23)
Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. (2014) (23)
Phase I Study of High-Stringency CD8 Depletion of Donor Leukocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation (2009) (22)
Recommendations of the European Working Group for Adult ALL (2011) (22)
The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults (2017) (21)
Poor Richard's Almanack (2015) (20)
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study (2021) (18)
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies (2018) (18)
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3‐mutated acute myeloid leukaemia and severe COVID‐19 (2020) (17)
JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia (2018) (17)
Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus. (2020) (16)
Cytomegalovirus pre‐emptive therapy after hematopoietic stem cell transplantation in the era of real‐time quantitative PCR: comparison with recipients of solid organ transplants (2016) (15)
Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. (2020) (14)
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. (2019) (14)
Recent Developments in the Management of T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (2012) (14)
Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant. (2019) (13)
The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF. (2016) (12)
International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia (2011) (11)
An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE® Antibody Construct Blinatumomab (2014) (11)
X chromosome inactivation patterns in the elderly (1997) (10)
Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317) (2015) (10)
Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study (2020) (10)
Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study (2013) (10)
Philadelphia-positive acute lymphoblastic leukemia--is bone marrow transplant still necessary? (2011) (10)
High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults (2015) (9)
Response: Chemotherapy or allografting for young adults with high-risk ALL? (2008) (9)
Detection and significance of bone marrow infiltration at the time of autologous bone marrow transplantation in Hodgkin's disease (1994) (8)
Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14 (2013) (8)
Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion (2007) (8)
CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. (2020) (8)
Measles virus: Improving natural oncolytic properties by genetic engineering (2004) (7)
Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. (2019) (7)
First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006) (2019) (7)
Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups (2010) (7)
Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell‐origin of ALL subgroups – a UKALLXII study (2010) (7)
Single nucleotide polymorphism array‐based signature of low hypodiploidy in acute lymphoblastic leukemia (2021) (7)
Peripheral blood progenitor cells versus bone marrow. (1994) (7)
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study. (2019) (7)
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (2007) (6)
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial (2022) (6)
Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) (2014) (6)
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. (2017) (6)
Gene therapy for B cell lymphomas. (1997) (6)
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials (2021) (6)
Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14 (2019) (6)
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study (2020) (5)
Emerging Pharmacotherapies for Adult Patients with Acute Lymphoblastic Leukemia (2012) (5)
Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study (2013) (5)
ABC of clinical haematology: The future of haematology, molecular biology, and gene therapy (1997) (5)
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity (2020) (5)
HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice (2017) (5)
IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. (2021) (5)
SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome (2014) (5)
Acute promyelocytic leukaemia (1994) (5)
First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006) (2021) (5)
Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation (2016) (4)
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2013) (4)
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial (2022) (4)
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII (2016) (4)
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial (2010) (4)
Lack of specificity of cell‐surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein (2002) (4)
Invasive aspergillosis in cancer patients. (1993) (4)
The value of molecular monitoring for residual disease (MRD) in early morphological remitters among adults diagnosed with B cell ALL and treated according to the MRC UKALL12 protocol. (2005) (3)
POST-INDUCTION MRD PREDICTS HIGH RELAPSE RISK FOLLOWING REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION: A PROSPECTIVE STUDY OF ADULT ALL (UKALL14, ISRCTN 66541317) (2017) (3)
803. The Effects of Intratumoral Injection of a Replicating Morbillivirus in a Canine Model of Naturally Occurring Lymphoma (2005) (3)
Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study. (2015) (3)
Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL (2020) (2)
Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy. (1996) (2)
Proceedings of Patient Reported Outcome Measure’s (PROMs) Conference Oxford 2017: Advances in Patient Reported Outcomes Research (2017) (2)
OPEN-LABEL, SINGLE-ARM, MULTICENTER CONFIRMATORY PHASE 2 STUDY OF THE BITE (R) ANTIBODY BLINATUMOMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA (2014) (2)
S1621 CLINICAL EFFICACY OF A NOVEL VALIDATED PROGNOSTIC INDEX FOR TRIAL DESIGN IN ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA. (2019) (2)
The clinical characteristics , therapy and outcome of 85 adults with acute lymphoblastic leukemia and t ( 4 ; 11 ) ( q 21 ; q 23 ) / MLL-AFF 1 prospectively treated on UKALLXII / ECOG (2013) (2)
Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma (2014) (2)
Comparative analysis of melphalan versus busulphan T‐cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia (2019) (2)
The Relevance of CD20 Targeting of Oncolytic Measles Virus in the Treatment of Adult Acute Lymphoblastic Leukemia (2017) (1)
Cancer vaccines: unanswered questions (2002) (1)
Barriers To Clinical Trial Enrolment For Teenagers and Young Adults With Acute Lymphoblastic Leukaemia: The Impact of Age Eligibility Criteria (2013) (1)
Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia (2019) (1)
Molecular monitoring of residual disease (MRD) during induction and intensification phases in low risk adult B cell ALL treated according to the MRC UKALL12 protocol. (2005) (1)
Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO (2019) (1)
randomized prospective trial (UKALL XII/ECOG 2993) immunophenotype, cytogenetics, and outcome from the large T-cell acute lymphoblastic leukemia in adults: clinical features, (2013) (1)
T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies (2008) (1)
Editors’ Introduction to special issue (2020) (1)
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO (2020) (1)
Prognostic Factors in Adult Acute Lymphoblastic Leukemia (ALL) (2011) (1)
Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia. (2022) (1)
Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials (2019) (1)
Excellent Outcome for Adults and Older Adolsecents Following Reduced Intensity Allogeneic Haematopoietic Stem Cell Transplantation for Inherited Primary Immune Deficiencies (PID). (2014) (1)
Of dogs and men: Canine distemper virus as model system for measles virus (2001) (1)
En-Abl-ing treatment of "Ph-like" ALL? (2019) (1)
Acute Lymphoblastic Leukaemia (ALL) Cells and Commonly-Used Chemotherapy Drugs Can Induce Bone Marrow-Derived Mesenchymal Stromal Cells to Become Cancer Associated Fibroblasts (CAF), Leading to Enhanced ALL Proliferation and Treatment Resistance (2017) (1)
Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993) (2008) (1)
Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data (2019) (1)
Utility of FDG-PET/CT in Lymphoblastic Lymphoma (2019) (1)
Reduced intensity allogeneic stem cell transplantation in patients with myelofibrosis (2006) (1)
Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol. (2005) (1)
Adult Acute Lymphoblastic Leukemia (2011) (1)
Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma (2011) (0)
Favorable outcomes in elderly and high-risk patients with AML and MDS following T-cell depleted reduced intensity conditioned allogeneic stem cell transplantation (2012) (0)
Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma. (1995) (0)
Clinical effect of Imatinib following remission induction in adult Philadelphia chromosome-positive acute lymphoblastic leukaemia: early results from the MRC UKALL12 Study (2006) (0)
Melphalan 140mg/m“2” significantly reduces 5 year progression free survival in multiple myeloma patients receiving a peripheral blood autologous stem cell transplant compared with melphalan 200mg/m“2” (2015) (0)
Minimal residual disease monitoring in adult acute lymphoblastic leukaemia in the UK; a multi-centre laboratory feasibility study (2010) (0)
The impact of imatinib therapy on adult Philadelphia positive acute lymphoblastic leukaemia (ALL): Early results from the UKALL12/ECOG 2993 study (2005) (0)
Age specific incidence of partner gene and secondary abnormalities in MLL positive acute lymphoblastic leukaemia (ALL) (2015) (0)
PF173 RESULTS FROM UKALL60+, A UK PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA (2019) (0)
How Does Autografting Cure Aggressive Malignant Non-Hodgkin’s Lymphoma? (2020) (0)
Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplantation for Adult De Novo Acute Lymphoblastic Leukemia: A Proespective Study from the UKALL14 Trial (ISRCTN 66541317) (2016) (0)
FEASIBILITY OF RADIOTHERAPY AS CONSOLIDATION POST BEAM AUTOGRAFT FOR HODGKINS-DISEASE (1993) (0)
ABC of Clinical Haematology (2007) (0)
RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA (2017) (0)
during Acute Inflammation Viral IL-6 Blocks Neutrophil Infiltration (2017) (0)
G-CSF after PBSC transplantation (1998) (0)
Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) (2010) (0)
P547: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA TREATED WITH VENETOCLAX COMBINATION THERAPY: REAL-WORLD EXPERIENCE IN BOTH FRONTLINE AND RELAPSED/REFRACTORY SETTINGS (2022) (0)
in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993 (2015) (0)
Severe airflow obstruction is a risk factor for unplanned admission among day surgery patients: 2AP2-5 (2008) (0)
CD20 EXPRESSION IN ADULTS WITH PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) FROM UKALL14, ITS REGULATION BY DEXAMETHASONE AND RITUXIMAB INDUCED CYTOTOXICITY (2014) (0)
Letter to the editor regarding: Selective non-operative management for penetrating extremity trauma: A paradigm shift in management. (2019) (0)
(ALL); an MRC UKALL12/ECOG 2993 study Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (2012) (0)
Allogeneic Stem Cell Transplantation for acute lymphoblastic leukaemia (ALL) (2009) (0)
TELOMERE DNA CONTENT AND TP53 STATE PROVIDE AN INSIGHT INTO GENOMIC INSTABILITY IN OLDER ADULT PATIENTS WITH ALL (2014) (0)
Final results of UK multi-centre, phase II study of Campath-1h dose de-escalation prior to non-myeloablative hla-identical sibling stem cell transplantation (2010) (0)
In vivo Campath-1h is associated with a high incidence of EBV viraemia but low risk of PTLD following allogeneic stem cell transplantation (2010) (0)
Viral therapy of cancer; measles virus (2008) (0)
PF160 IKZF1 DELETIONS DO NOT HAVE A STRONG IMPACT ON EVENT FREE SURVIVAL IN PATIENTS WITH B-PRECURSOR ALL TREATED ON THE UKALL14 TRIAL (ISRCTN 66541317) (2019) (0)
INITIAL RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (2016) (0)
How Does Measles Virus Kill Cancer Cells? Characterizing Oncolytic Measles Virus (OMV) Kinetics in a Mesenchymal Stromal Cell (MSC) Model of Cellular Transformation (2014) (0)
Mesenchymal Stromal Cells Are Promising Candidates as Delivery Vehicles for Systemic Oncolytic Measles Virotherapy in Models of Acute Lymphoblastic Leukaemia (2012) (0)
Title given: Ph+ ALL: Is Chemo+TKI or Transplant the Best Road to Cure? Title suggested: Curing Ph+ ALL: Assessing the relative contributions of chemotherapy, TKI and allogeneic stem cell transplant (2020) (0)
Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients (2015) (0)
Neutrophils (PMNs) in Measles Virus (MV) Mediated Leukaemia Therapy: Good or Bad? (2014) (0)
IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions (2022) (0)
Cheidelberg. 1994. No of pages: 711. R.E. Price: DM 278.00 (soft cover). ISBN: 3-540-57753-X (1995) (0)
Allogeneic stem cell transplantation in patients with common variable immunodeficiency (2011) (0)
Bone Marrow Infiltrating T-Cell Signatures Following Allo-HCT for Adult Acute Lymphoblastic Leukaemia Differentiate between Patients in Continuous CR and Those with Persistent Minimal Residual Disease or Relapse (2017) (0)
Human Bone Marrow-Derived Mesenchymal Stromal Cells Permit Delivery, and Enhance Efficacy of Systemically Administered Oncolytic Measles Virotherapy to Disseminated Human Pre-B ALL Murine Xenograft Models in the Presence of Humoral Immunity (2013) (0)
Polymorphonuclear Neutrophils(PMNs) Are Cytotoxic for Measles Virus (MV)-Infected Tumor Cells Ex-Vivo, but Their Role in MV-Mediated Oncolysis In-Vivo Is Tumor-Type Dependent (2012) (0)
Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination (2022) (0)
LYMPHOID NEOPLASIA Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia (2017) (0)
Syddansk Universitet Perspectives of patients and professionals on the use of patient reported outcome measures in primary care a systematic review of qualitative studies (0)
Abstract 3428: Aging, telomere and TP53: a potential biological insight into the mechanistic origin of acute lymphoblastic leukemia (ALL) in the elderly (2015) (0)
Effects on Human Neutrophil Function Measles Virus Infection Has Pleiotropic Attenuated, Oncolytic, but Not Wild-Type (2011) (0)
Bcl-2 over-expression results in decreased measles virus mediated cytotoxicity in lymphoma cell lines. (2002) (0)
xenografts in immunodeficient mice Live attenuated measles virus induces regression of human lymphoma (2013) (0)
Targeting the cytotoxicity of a fusogenic gibbon ape leukaemia virus envelope glycoprotein by ligand display. (1999) (0)
Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma (2020) (0)
PF721 MINIMAL CLINICALLY IMPORTANT DIFFERENCE AND RESPONSIVENESS FOR HM-PRO IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES (2019) (0)
663. Can Oncolytic Measles Virus Targeted to CD20 Recapitulate Any of the Effects of Rituximab in the Treatment of Acute Lymphoblastic Leukemia (2016) (0)
Type 1 IFN Response Is a Major Determinant of Oncolytic Measles Virus Activity in a Model of Sequential Stromal Cell Transformation (2017) (0)
FUNCTIONAL STUDIES OF IK6 EXPRESSION SHED LIGHT ON THE COOPERATING MECHANISMS UNDERLYING THE GAIN OF MALIGNANCY IN B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (2014) (0)
Health-related quality of life issues in patients with haematological malignancy: a qualitative study (2016) (0)
ARF way to Ph+ ALL stratification? (2018) (0)
Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study (2012) (0)
Attenuated measles virus therapy for lymphoma (2001) (0)
TP53 Alterations Are Frequent in Patients over 60 Years with B-Precursor Acute Lymphoblastic Leukemia (ALL) and Low Hypodiploid/Near Triploid (HoTr) Karyotype; They Correlate with RB1 Deletion and Leukemic Telomere Gain (2014) (0)
DEVELOPMENT OF A NEW HAEMATOLOGICAL MALIGNANT PATIENT-REPORTED OUTCOME MEASURE FOR USE IN CLINICAL PRACTICE: HM-PRO (2017) (0)
968. Next Generation Measles Virus Vectors for Oncolytic Therapy: Targeted, Armed and Stealth (2006) (0)
Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia (2022) (0)
Attenuated Measles Virus: A Promising Therapeutic Modality for B Cell Malignancy. (2009) (0)
Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance (2022) (0)
Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID) (2016) (0)
Fusogenic membrane glycoproteins - A novel class of cytotoxic genes with immunostimulatory properties. (1999) (0)
Inhibition of survivin expression suppresses the growth of transformed large cell non-Hodgkin lymphoma. (2002) (0)
Ph+ ALL: Is Chemo+TKI or Transplant the Best Road to Cure? (2019) (0)
Recurrent MEF2D Fusions Define A New Subtype of Acute Lymphoblastic Leukemia Associated with Older Age at Diagnosis and Poor Outcome (2016) (0)
Blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia: An open-label, single-arm, multicenter confirmatory phase 2 study (2014) (0)
JAK-ing up treatment for CRLF2-R ALL. (2022) (0)
Frequency of IKZF1 Deletions in a Peruvian Population with B-Cell Acute Lymphoblastic Leukemia (2020) (0)
292. Primary Chronic Lymphocytic Leukaemia Cells Are Resistant to the Oncolytic Effects of Attenuated Measles Virus (2005) (0)
Measles as an Oncolytic Virus (2008) (0)
65. Oncolytic Measles Virus Differentially Affects Mitochondrial Biogenesis in Transformed versus Non-Transformed BM-Derived MSCs (2016) (0)
Whole Genome Profiling of Adult B-Other Acute Lymphoblastic Leukaemia on the UKALL14 Trial (2019) (0)
MVhGCSF Is Therapeutic In-Vivo B Cell Malignancies With Neutrophils (PMNs) Playing Different Roles (2015) (0)
The Role of Mitochondrial RNA from B-Precursor Acute Lymphoblastic Leukaemia Cells in Generating a Chemoprotective Bone Marrow Niche (2022) (0)
University of Southern Denmark Perspectives of patients and professionals on the use of patient reported outcome measures in primary care a systematic review of qualitative studies (2017) (0)
A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care (2023) (0)
Vaccine Measles Virus Has Therapeutic Potential In B Cell Malignancy (2010) (0)
An Optimised In Vivo Modelling System For Adult Acute Lympoblastic Leukaemia (ALL) Enables Sensitive Detection Of Leukaemia Initiating Cells (LIC) and Drug Resistant Clones (2013) (0)
IKZF1 Delta 4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PREDICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14 TRIAL (2017) (0)
Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT) (2014) (0)
Acknowledgment of Reviewers 2021. (2021) (0)
Difficulties of using clonal analysis for diagnosis of haematological disorders in elderly patients (1996) (0)
Commonly Used Chemotherapy Drugs Differentially Determine Microenvironment-Mediated Protection, Via Mitochondrial Transfer, to B-Precursor Acute Lymphoblastic Leukaemia Cells (2018) (0)
Activation of the LMO2 Oncogene in T-ALL through a Somatically Acquired Neomorphic Promoter (2016) (0)
Human Bone Marrow Organoids Enable the Study of Hematopoietic Cell-Stromal Interactions and Support the Survival of Malignant Cells from Patients (2022) (0)
Fusion Between Neutrophils (PMN) and Target Cells Mediate Cytotoxicity During Measles Virus (MV) Oncolysis - A Novel Mechanism (2015) (0)
Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial (2013) (0)
Clinical utility of whole genome sequencing in hematological neoplasms. (2021) (0)

This paper list is powered by the following services:

Other Resources About Adele Fielding

en.wikipedia.org

What Schools Are Affiliated With Adele Fielding?

Adele Fielding is affiliated with the following schools: